• About Us
    • Our Company
    • Our People
  • Our Science
    • Our Science
    • Precise Antibody Engineering
    • Cytokine-Fusion Antibody
    • Novel T cell Targets
  • Pipeline
    • Pipeline
    • MMB101
    • MMB102
    • MFA011
  • Partnering
  • News
  • About Us
    • Our Company
    • Our People
  • Our Science
    • Our Science
    • Precise Antibody Engineering
    • Cytokine-Fusion Antibody
    • Novel T cell Targets
  • Pipeline
    • Pipeline
    • MMB101
    • MMB102
    • MFA011
  • Partnering
  • News

  • About us
    • Our Company
    • Our People
  • Contact
  • Home
  • Our Science
    • Cytokine-Fusion Antibody
    • Novel T cell Targets
    • Precise Antibody Engineering
  • Partnering with Us
  • Pipeline
    • MFA011
    • MMB101
    • MMB102

News

2021-10-28

MediMabBio takes first step towards commercialization with Thermo Fisher CDMO Contract

2021-06-28

MediMabBio has made a collaboration deal with University Hospitals Birmingham for immunotherapy cancer drug development

2021-02-15

MediMabBio has successfully completed a Series-A fundraising with 18 million USD

2020-05-27

MediMabBio establishes UK Subsidiary, MediMab Biotherapeutics

2019-02-19

MediMabBio Secures $3 Million Investment to Advance “New-Generation Cancer Treatment”

2017-07-26

MediMabBio Chosen for Up to $1 Million Funding from the TIPS Program

  • «
  • 1
  • 2

  • Home
  • Our Company
    • Our Company
    • Our People
  • Our Science
    • Our Science
    • Precise Antibody Engineering
    • Cytokine-Fusion Antibody
    • Novel T cell Targets
  • Pipeline
    • Pipeline
    • MMB101
    • MMB102
    • MFA011
  • Partnering with Us
  • News
  • Contact

#721, 54, Changeop-ro, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea, 13449 Tel. 82-(0)31-623-2100 Fax. 82-(0)31-751-2101 Email. info@medimabbio.com

©MEDIMABBIO. ALL RIGHTS RESERVED.